Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00029614
NCT00029614
Completed
Phase 2

Psychopharmacology of Adolescents With AUD and ADHD

University of Pittsburgh1 site in 1 country24 target enrollmentMay 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSubstance Use DisordersAttention Deficit Hyperactivity Disorder
DrugsAtomoxetine

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Substance Use Disorders
Sponsor
University of Pittsburgh
Enrollment
24
Locations
1
Primary Endpoint
decrease in ADHD symptoms
Status
Completed
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).

Registry
clinicaltrials.gov
Start Date
May 2006
End Date
July 2007
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Adolescents, ages 13-18
  • •Meets criteria for alcohol and/or substance use disorder and attention deficit hyperactivity disorder.

Exclusion Criteria

  • •Adolescents who are pregnant.
  • •Have a history of seizure disorder, other neurological or medical disorder for which medication treatment may present a considerable risk.
  • •History of pervasive development disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders.
  • •Currently on other psychotropic medications from which discontinuation would present a significant risk.
  • •A current episode of major depressive disorder or a diagnosis of bipolar disorder.
  • •Diagnosis of dependence for any substance other than marijuana.
  • •Adolescents with a full-scale IQ below 80.

Outcomes

Primary Outcomes

decrease in ADHD symptoms

decrease in the quantity and frequency of alcohol and other substance use

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 4
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young ChildrenAttention Deficit Disorder With Hyperactivity
NCT00254462University of Nebraska93
Completed
N/A
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment FacilityAttention Deficit Hyperactivity Disorder
NCT00953862NYU Langone Health18
Completed
Phase 4
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum DisorderAutistic DisorderAttention Deficit Disorder With Hyperactivity
NCT00380692Eli Lilly and Company97
Completed
Phase 3
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/AdolescentsAttention Deficit Hyperactivity Disorder
NCT00191659Eli Lilly and Company200
Completed
Phase 4
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesAttention Deficit Hyperactivity Disorder
NCT00510276Eli Lilly and Company445